Sunita Keshari et al. demonstrated that adding TREM2 blockade to neoantigen cancer vaccines or immune checkpoint therapies enhanced tumor-specific CD8+ T-cell expansion and improved tumor control [145]. Here, CD8A is linked to neoplasm.